Zavesca

Zavesca is a brand name of miglustat, approved by the FDA in the following formulation(s):

ZAVESCA (miglustat - capsule; oral)

• 
  Manufacturer: ACTELION PHARMS LTD
  
  Approval date: July 31, 2003
  
  Strength(s): 100MG ^[RLD]

Has a generic version of Zavesca been approved?

No. There is currently no therapeutically equivalent version of Zavesca available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zavesca. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method of inhibiting glycolipid synthesis
  Patent 5,472,969
  Issued: December 5, 1995
  Inventor(s): Platt; Frances M. & Neises; Gabrielle R. & Dwek; Raymond A. & Butters; Terry D.
  Assignee(s): Monsanto Company
  A method is disclosed for inhibiting the biosynthesis of glycolipids in cells capable of producing glycolipids comprising subjecting said cells to a glycolipid inhibitory effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which said alkyl contains from 2-8 carbon atoms.
  
  Patent expiration dates:
  
  
  • May 13, 2013
    
  
  



• 
  Method of inhibiting glycolipid synthesis
  Patent 5,525,616
  Issued: June 11, 1996
  Inventor(s): Platt; Frances M. & Neises; Gabrielle R. & Dwek; Raymond A. & Butters; Terry D.
  Assignee(s): Monsanto Company
  A method is disclosed for inhibiting the biosynthesis of glycolipids in cells capable of producing glycolipids comprising subjecting said cells to a glycolipid inhibitory effective amount of an N-alkyl derivative of 1,5-dideoxy-1,5-imino-D-glucitol in which said alkyl contains from 2-8 carbon atoms.
  
  Patent expiration dates:
  
  
  • June 11, 2013
    
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • July 31, 2010 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Zavesca Consumer Information (Drugs.com)
• Zavesca Consumer Information (Wolters Kluwer)
• Zavesca Consumer Information (Cerner Multum)
• Zavesca Advanced Consumer Information (Micromedex)
• Zavesca AHFS DI Monographs (ASHP)
• Miglustat Consumer Information (Wolters Kluwer)
• Miglustat Consumer Information (Cerner Multum)
• Miglustat Advanced Consumer Information (Micromedex)
• Miglustat AHFS DI Monographs (ASHP)